+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Oxyntomodulin : a novel potential treatment for obesity

Oxyntomodulin : a novel potential treatment for obesity

Treatments in Endocrinology 5(5): 265-272

The prevalence of obesity is increasing rapidly and the associated morbidity and mortality has led to an urgent need for potential therapeutic targets to reduce appetite and food intake. Gut hormones released after eating that coordinate digestive activity and promote satiety are novel potential treatments for obesity. Oxyntomodulin is a gut hormone that is produced by the L cells in the small intestine and reduces food intake. It is timely to review some of the original literature on oxyntomodulin, to evaluate what is already known about the peptide, and also to set the recent findings on its effects on food intake and bodyweight into context.Recent studies have shown that long-term peripheral administration of oxyntomodulin to rats leads to reduced food intake and reduced weight gain. Studies in humans have demonstrated that acute administration reduces food intake by 19%. When given preprandially by subcutaneous injection three times daily, oxyntomodulin resulted in a reduction in food intake and mean weight loss of 2.8kg over 4 weeks. Oxyntomodulin thus represents a potential therapy for obesity.The mechanism of action of oxyntomodulin is not known. Current evidence suggests that it acts via the glucagon-like peptide 1 (GLP-1) receptor. There may be an additional receptor in the gastric mucosa mediating its effects on gastric acid secretion. Although oxyntomodulin probably acts via the GLP-1 receptor, the two peptides differentially regulate food intake and energy expenditure in the mouse.Oxyntomodulin represents a potential therapy for obesity. Further work will help to clarify its mechanisms of action.

(PDF emailed within 1 workday: $29.90)

Accession: 049839277

Download citation: RISBibTeXText

PMID: 17002486

Related references

The mechanism of action for oxyntomodulin in the regulation of obesity. Current Opinion in Investigational Drugs 11(10): 1151-1157, 2011

Oxyntomodulin and oxyntomodulin 19 37 as regulators of gastric acid secretion. Digestion 46(SUPPL 1): 47, 1990

Oxyntomodulin 19-37, but not tGLP-1, inhibits neurally-stimulated pancreatic secretion at doses mimicking post-prandial plasma oxyntomodulin-like immunoreactivity in the rat. Digestion 58(SUPPL 2): 44, 1997

Crystallization and preliminary x-ray analysis of anti-obesity peptide hormone oxyntomodulin. Protein and Peptide Letters 15(2): 232-234, 2008

Action and therapeutic potential of oxyntomodulin. Molecular Metabolism 3(3): 241-251, 2014

Expression of oxyntomodulin in bifidobacteria and effect of oxyntomodulin-transformed bifidobacteria on the body weight of obese mice. Nan Fang Yi Ke Da Xue Xue Bao 29(9): 1796-1798, 2011

Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Experimental and Clinical Endocrinology & Diabetes 106 Suppl 2: 35-40, 1998

Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. Journal of Clinical Endocrinology and Metabolism 74(6): 1405-1409, 1992

Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 62(6): 1945-1956, 2013

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obesity Reviews 12(8): 593-601, 2011

An obesity dietary quality index predicts abdominal obesity in women: potential opportunity for new prevention and treatment paradigms. Journal of Obesity 2010: -, 2010

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. European Journal of Clinical Investigation 18(5): 499-503, 1988

Isolation of alligator gar (Lepisosteus spatula) glucagon, oxyntomodulin, and glucagon-like peptide: amino acid sequences of oxyntomodulin and glucagon-like peptide. General and Comparative Endocrinology 69(1): 133-140, 1988

Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. British Journal of Pharmacology 170(7): 1333-1348, 2014